Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,994

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,592

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Vincent, M. J., Bergeron, É., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,831

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J. H., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 731

Whipple's Disease

Fenollar, F., Puéchal, X., & Raoult, D. (2007) · New England Journal of Medicine · doi:10.1056/nejmra062477 · Cited by 651

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. H., & Ranst, M. A. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 644

New insights into the antiviral effects of chloroquine

Savarino, A., Trani, L. D., Donatelli, I., Cauda, R., & Cassone, A. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70361-9 · Cited by 570

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

Al‐Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 477

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Colson, P., Rolain, J., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 471

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

Rolain, J., Colson, P., & Raoult, D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.05.015 · Cited by 408

SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges

Soufi, G. J., Hekmatnia, A., Nasrollahzadeh, M., Shafiei, N., Sajjadi, M., Iravani, P., Fallah, S., Iravani, S., & Varma, R. S. (2020) · Applied Sciences · doi:10.3390/app10103641 · Cited by 41

Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19

Casey, J. D., Johnson, N. J., Semler, M. W., Collins, S. P., Aggarwal, N. R., Brower, R. G., Chang, S. Y., Eppensteiner, J. C., Filbin, M. R., Gibbs, K. W., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-478sd · Cited by 43

Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin

Ejuh, G. W., Fonkem, C. C., Assatse, Y. T., Kamsi, R. A. Y., Nya, F. T., Ndukum, L. P., & Ndjaka, J. M. B. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04647 · Cited by 42

Brief review on repurposed drugs and vaccines for possible treatment of COVID-19

De, P., Chakraborty, I., Karna, B., & Mazumder, N. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173977 · Cited by 46

Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report

Hong, L. A., Smith, N., Keerthy, M., Lee-Griffith, M., Garcia, R., Shaman, M., & Goyert, G. L. (2020) · Case Reports in Women s Health · doi:10.1016/j.crwh.2020.e00217 · Cited by 41

Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent

Pindiprolu, S. K. S. S., Kumar, C. S. P., Golla, V. S. K., Likitha, P., Shreyas Chandra, K., Esub Basha, S. K., & Rn, R. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109858 · Cited by 41

Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review

Mehraeen, E., Najafi, Z., Hayati, B., Javaherian, M., Rahimi, S., Dadras, O., SeyedAlinaghi, S., Ghadimi, M., & Sabatier, J. (2021) · Infectious Disorders - Drug Targets · doi:10.2174/1871526521666210726150435 · Cited by 41

Diacerein: A potential multi-target therapeutic drug for COVID-19

de Oliveira, P. G., Termini, L., Durigon, E. L., Lepique, A. P., Sposito, A. C., & Boccardo, E. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109920 · Cited by 41

Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2

Zhang, Y., Hu, S., Wang, J., Xue, Z., Wang, C., & Wang, N. (2020) · Virology · doi:10.1016/j.virol.2020.12.001 · Cited by 42

Synthesis and potential antimicrobial activity of novel α-aminophosphonates derivatives bearing substituted quinoline or quinolone and thiazole moieties

Litim, B., Djahoudı, A., Meliani, S., & Boukhari, A. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02815-5 · Cited by 41

Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2

Wang, Q., Zhao, Y., Chen, X., & Hong, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1817786 · Cited by 40

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence

Venerito, V., Lopalco, G., & Iannone, F. (2020) · Rheumatology International · doi:10.1007/s00296-020-04566-9 · Cited by 40

Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin

Gabriels, J. K., Saleh, M. A., Chang, D., & Epstein, L. M. (2020) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2020.03.017 · Cited by 40

Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection

Infante, M., Ricordi, C., Alejandro, R., Caprio, M., & Fabbri, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1799785 · Cited by 40

SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19

Dakal, T. C. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152021 · Cited by 43

A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol.

Jamaati, H., Dastan, F., Tabarsi, P., Marjani, M., Saffaei, A., & Hashemian, S. M. R. (2020) · PubMed Central · doi:10.22037/ijpr.2020.113337.14239 · Cited by 39

Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model

Yang, J., Wu, M., Liu, X., Liu, Q., Guo, Z., Yao, X., Liu, Y., Cui, C., Li, H., Song, C., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574720 · Cited by 44

Hydroxychloroquine in COVID-19 Patients: Pros and Cons

Younis, N. K., Zareef, R. O., Hassan, S. A., Bitar, F. F., Eid, A. H., & Arabi, M. T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.597985 · Cited by 41

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview

Rezaee, H., Pourkarim, F., Pourtaghi-anvarian, S., Entezari-Maleki, T., Asvadi-Kermani, T., & Nouri-vaskeh, M. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.705 · Cited by 31

A review of Cameroonian medicinal plants with potentials for the management of the COVID-19 pandemic

Fedoung, E. F., Biwôlé, A. B., Biyegue, C. F. N., Tounkam, M. N., Ntonga, P. A., Nguiamba, V. P., Essono, D. M., Funwi, P. F., Tonga, C., Nguenang, G. M., et al. (2021) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-021-00567-6 · Cited by 43

Antimicrobial and antiproliferative activity studies of some new quinoline-3-carbaldehyde hydrazone derivatives

Püsküllü, M. O., Çeli̇k, İ., Erol, M., Fatullayev, H., Uzunhisarcıklı, E., & Kuyucuklu, G. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104014 · Cited by 38

Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics

Kabra, R., & Singh, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165978 · Cited by 38

Mechanisms of action by antimicrobial agents: A review

Singh, S. P., Qureshi, A., & Hassan, W. M. (2021) · McGill Journal of Medicine · doi:10.26443/mjm.v19i1.217 · Cited by 42

Coronavirus disease 2019 (COVID-19) and autoimmunity

Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41

Quinolines derivatives as promising new antifungal candidates for the treatment of candidiasis and dermatophytosis

Machado, G. D. R. M., Diedrich, D., Ruaro, T. C., Zimmer, A. R., Teixeira, M. L., de Oliveira, L. F., Jean, M., van de Weghe, P., de Andrade, S. F., Gnoatto, S. C. B., et al. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00348-4 · Cited by 37

Impact of COVID-19 on the aquatic environment and implications for fisheries with special emphasis to Indian perspective

Prasad, G. S., Rout, S. K., Amin, A., Malik, M. M., Ahmad, I., Rather, M. A., Karmakar, S., Khalil, H. S., & Abubakar, A. (2024) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-024-00289-8 · Cited by 37

The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge

Xia, L., Chen, J., Friedemann, T., Yang, Z., Ling, Y., Liu, X., Lu, S., Li, T., Song, Z., Huang, W., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa286 · Cited by 38

Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications

Kumar, R., Sharma, A., Srivastava, J. K., Siddiqui, M. H., Uddin, M. S., & Aleya, L. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-12200-1 · Cited by 39

SARS-CoV-2: From the pathogenesis to potential anti-viral treatments

Zarandi, P. K., Zinatizadeh, M. R., Zinatizadeh, M., Yousefi, M. H., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111352 · Cited by 37

COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights

Neri, P., & Pichi, F. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01389-2 · Cited by 37

Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting

Nielsen, K., Bonnesen, B., Hansen, E. F., Jensen, J. S., Lapperre, T. S., Weinreich, U. M., & Hilberg, O. (2020) · European Clinical Respiratory Journal · doi:10.1080/20018525.2020.1761677 · Cited by 36

Risk of using hydroxychloroquine as a treatment of COVID-19

Alanagreh, L., Alzoughool, F., & Atoum, M. F. M. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200024 · Cited by 36

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus

Prashantha, C. N., Gouthami, K., Lavanya, L., Bhavanam, S., Jakhar, A., Shakthiraju, R. G., Suraj, V., Sahana, K. V., Sujana, H. S., Guruprasad, N. M., et al. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107769 · Cited by 40

COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

Ho, W. S., Zhang, R., Tan, Y. L., & Chai, C. L. L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106201 · Cited by 37

Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon

Haşlak, F., Yıldız, M., Adroviç, A., Barut, K., & Kasapçopur, Ö. (2020) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2020.2020.4.43 · Cited by 35

Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice

Pan, Z., Chang, Y., Han, N., Hou, F., Lee, B. J. Y., Zhi, F., Yang, R., & Bi, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118450 · Cited by 35

In what area of biology has a “new” type of cell death been discovered?

Wang, X., Lin, J., Li, Z., & Wang, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188955 · Cited by 35

Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein – an in silico insight into the comparative efficacy of repurposing antiviral drugs

Amin, M. U., & Abbas, G. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1775703 · Cited by 36

Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Huang, B., Ling, R., Cheng, Y., Wen, J., Dai, Y., Huang, W., Zhang, S., Lu, X., Luo, Y., & Jiang, Y.-Z. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.013 · Cited by 38

A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment

Kumar, R., Kumar, V., & Lee, K. W. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104186 · Cited by 35

The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy

Kouhpayeh, S., Shariati, L., Boshtam, M., Rahimmanesh, I., Mirian, M., Esmaeili, Y., Najaflu, M., Khanahmad, N., Zeinalian, M., Trovato, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115438 · Cited by 35

Does hydroxychloroquine combat COVID-19? A timeline of evidence

Alia, E., & Grant-Kels, J. M. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.031 · Cited by 34

Febuxostat therapy in outpatients with suspected COVID‐19: A clinical trial

Davoodi, L., Abedi, S. M., Salehifar, E., Alizadeh‐Navaei, R., Rouhanizadeh, H., Khorasani, G., & Hosseinimehr, S. J. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13600 · Cited by 33

Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19

D’Acquarica, I., & Agranat, I. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.021 · Cited by 34

The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway

Carrière, F., Longhi, S., & Record, M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.05.013 · Cited by 35

Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection

Bhatti, J. S., Bhatti, G. K., Khullar, N., Reddy, A. P., & Reddy, P. H. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02074-2 · Cited by 34

COVID-19 therapy: What weapons do we bring into battle?

de Almeida, S. M. V., Soares, J. C. S., dos Santos, K. L., Alves, J. E. F., Ribeiro, A. G., Jacob, Í. T. T., Ferreira, C. J. D. S., dos Santos, J. C., de Oliveira, J. F., de Carvalho, L. B., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115757 · Cited by 36

Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach

O'Donovan, S. M., Imami, A. S., Eby, H., Henkel, N., Creeden, J. F., Asah, S. M., Zhang, X., Wu, X., Alnafisah, R. S., Taylor, R. T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84044-9 · Cited by 41

COVID-19 prediction using AI analytics for South Korea

Sinha, A., & Rathi, M. (2021) · Applied Intelligence · doi:10.1007/s10489-021-02352-z · Cited by 34

Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?

Menezes, C. R., Sanches, C., & Chequer, F. M. D. (2020) · Journal of Health & Biological Sciences · doi:10.12662/2317-3076jhbs.v8i1.3206.p1-9.2020 · Cited by 33

Advances in green liquid chromatography for pharmaceutical analysis: A comprehensive review on analytical greenness to sustainable chemistry approaches

Ahmed, M., Abdullah, Eiman, E., Al‐Ahmary, K. M., Aftab, F., Sohail, A., Raza, H., & Ali, I. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111400 · Cited by 34

A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine

Maillart, E., Leemans, S., Noten, H. V., Vandergraesen, T., Mahadeb, B. A., Salaouatchi, M. T., Bels, D. D., & Clevenbergh, P. A. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1774644 · Cited by 33

Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment

Muhammed, Y. (2020) · Biosafety and Health · doi:10.1016/j.bsheal.2020.07.002 · Cited by 33

COVID-19: The Immune Responses and Clinical Therapy Candidates

Zhand, S., Jazi, M. S., Mohammadi, S., Rasekhi, R. T., Rostamian, G., Kalani, M. R., Rostamian, A., George, J., & Douglas, M. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155559 · Cited by 35

Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments

Goodarzi, P., Mahdavi, F., Mirzaei, R., Hasanvand, H., Sholeh, M., Zamani, F., Sohrabi, M., Tabibzadeh, A., Jeda, A. S., Niya, M. H. K., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106885 · Cited by 33

SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review

Muhammed, Y., Nadabo, A. Y., Pius, M., Sani, B. E., Usman, J., Garba, N. A., Mohammed, J. S., Olayanju, B., Bala, S. Z., Abdullahi, M. G., et al. (2021) · Biosafety and Health · doi:10.1016/j.bsheal.2021.07.003 · Cited by 33

Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools

Hathout, R. M., AbdelHamid, S. G., & Metwally, A. A. (2020) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2020.100446 · Cited by 32

Therapeutic efficacy of macrolides in management of patients with mild COVID-19

Rashad, A., Nafady, A., Hassan, M. H., Mansour, H., Taya, U., Bazeed, S. E. S., Aref, Z. F., Sayed, M. A. A., Nafady‐Hego, H., & Abdelmaksoud, A. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95900-z · Cited by 32

Computational guided drug repurposing for targeting 2′-O-ribose methyltransferase of SARS-CoV-2

Sharma, K., Morla, S., Goyal, A., & Kumar, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118169 · Cited by 31

Novel coronavirus 2019 (COVID-19) pandemic outbreak: A comprehensive review of the current literature

Ullah, H., Ullah, A., Gul, A., Mousavi, T., & Khan, M. W. (2020) · Vacunas (English Edition) · doi:10.1016/j.vacun.2020.09.009 · Cited by 40

Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis

Tarique, M., Ahmad, S., Malik, A., Ahmad, I. S., Saeed, M., Almatroudi, A., Qadah, T., Murad, M. A., Mashraqi, M. M., Alam, Q., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-04027-8 · Cited by 31

Aspects About Science in the Context of Production and Communication of Knowledge of COVID-19

Maia, P. F., Justi, R., & dos Santos, M. A. R. (2021) · Science & Education · doi:10.1007/s11191-021-00229-8 · Cited by 31

The ecological impact of liquid chromatographic methods reported for bioanalysis of COVID-19 drug, hydroxychloroquine: Insights on greenness assessment

Shaaban, H. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.108145 · Cited by 33

COVID-19 Therapeutic and Prevention

Raoult, D., Hsueh, P., Stefani, S., & Rolain, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105937 · Cited by 31

The COVID-19 Pandemic: Changing Lives and Lessons Learned

Rohrich, R. J., Hamilton, K. L., Avashia, Y. J., & Savetsky, I. L. (2020) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000002854 · Cited by 31

Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)

Dı́az, E., Menéndez, R. A., Vidal, P., Escapa, M. G., Suberviola, B., Serrano, A., Marcos-Neira, P., Quintana‐Díaz, M., & González, M. C. (2020) · Medicina Intensiva · doi:10.1016/j.medin.2020.06.017 · Cited by 34

Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection

Konwar, M., & Sarma, D. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131761 · Cited by 30

Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress

Hossain, M. J., & Rahman, S. M. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1864327 · Cited by 32

Toxicity Evaluation and Effect-Based Identification of Chlorine Disinfection Products of the Anti-COVID-19 Drug Chloroquine Phosphate

Hu, S., Fang, S., Zhao, J. Q., Wang, G., Qi, W., Zhang, G., Huang, C., Qu, J., & Liu, H. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.2c08260 · Cited by 30

Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin

Olateju, O. A., Babalola, C. P., Olubiyi, O. O., Kotila, O. A., Kwasi, D. A., Oaikhena, A. O., & Okeke, I. N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.556550 · Cited by 29

COVID-19, An early investigation from exposure to treatment outcomes in Tehran, Iran

Ashraf, M. A., Shokouhi, N., Shirali, E., Tanha, F. D., Shirani, K., Memar, O. M., Kamalipour, A., Azarnoush, A., Mabadi, A., Ossareh, A., et al. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_1088_20 · Cited by 29

Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations

Karalis, V. D., Ismailos, G., & Karatza, E. (2020) · Safety Science · doi:10.1016/j.ssci.2020.104842 · Cited by 28

Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update

Pal, A., Pawar, A. T., Goswami, K., Sharma, P., & Prasad, R. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00900-x · Cited by 27

Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin

Sutanto, H., & Heijman, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.587709 · Cited by 28

COVID-19 healthcare policies in Ireland: A rapid review of the initial pandemic response

O’Leary, N., Kingston, L., Griffin, A., Morrissey, A., Noonan, M., Kelly, D., Doody, O., Niranjan, V. R., Gallagher, A., O’Riordan, C., et al. (2021) · Scandinavian Journal of Public Health · doi:10.1177/14034948211008371 · Cited by 30

Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments

Akter, R., Rahman, M. H., Bhattacharya, T., Kaushik, D. K., Mittal, V., Parashar, J., Kumar, K., Kabir, M. T., & Tagde, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16809-8 · Cited by 28

Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach

Sen, D., Debnath, B., Debnath, P., Debnath, S., Zaki, M. E. A., & Masand, V. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-05349-x · Cited by 28

Antiviral Potential of Plants against COVID-19 during Outbreaks—An Update

Jamal, Q. M. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113564 · Cited by 28

Recent advance in the development of N-heterocyclic derivatives as anti-SARS-CoV-2 inhibitors: A review

Ettahiri, W., Adardour, M., Alaoui, S., Allah, A. E. M. A., Aichouch, M., Salim, R., Ramli, Y., Bouyahya, A., & Taleb, M. (2024) · Phytochemistry Letters · doi:10.1016/j.phytol.2024.04.016 · Cited by 29

Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic

Scuccimarri, R., Sutton, E. D., & Fitzcharles, M. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200369 · Cited by 27

Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach

Dongala, T., Katari, N. K., Palakurthi, A. K., Katakam, L. N. R., & Marisetti, V. M. (2020) · Chromatographia · doi:10.1007/s10337-020-03945-5 · Cited by 27

Pharmacogenomics of genetic polymorphism within the genes responsible for SARS‐CoV‐2 susceptibility and the drug‐metabolising genes used in treatment

Al-Eitan, L., & Alahmad, S. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2194 · Cited by 22

COVID-19: inflammatory responses, structure-based drug design and potential therapeutics

Tripathi, N., Tripathi, N., & Goshisht, M. K. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10176-1 · Cited by 29

The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review

Das, S., Ramachandran, A. K., Birangal, S., Akbar, S., Ahmed, B., & Joseph, A. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100085 · Cited by 28

Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia

Pinzón, M. A., Arango, D. C., Betancur, J. F., Ortiz, S., Holguín, H., Arias, C. A., Palacio, B. J. M., Amarillo, M., Llano, J. F., & Montoya, P. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00460-9 · Cited by 28

In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea

Bajrai, L. H., El-Kafrawy, S. A., Hassan, A. M., Tolah, A. M., Alnahas, R. S., Sohrab, S. S., Rehan, M., & Azhar, E. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-26157-3 · Cited by 27

SARS‐CoV‐2: What do we know so far?

Khedkar, P. H., & Patzak, A. R. (2020) · Acta Physiologica · doi:10.1111/apha.13470 · Cited by 30

Perspective from Ecuador, the Second Country with More Confirmed Cases of Coronavirus Disease 2019 in South America: A Review

Hallo‐Carrasco, A., Rojas, A., & Hallo, C. (2020) · Cureus · doi:10.7759/cureus.7452 · Cited by 26

Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19

Saqrane, S., & Mhammedi, M. A. E. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100680 · Cited by 26

Patogênese e perspectivas de tratamento da Covid-19: uma revisão

Sousa, M. R. N., Barros, S. S., da Silva, M. M., Oliveira, A. P. M., Rocha, G. M. D. M., & de Oliveira, G. A. L. (2020) · Research Society and Development · doi:10.33448/rsd-v9i7.3730 · Cited by 26

Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation

El-hoshoudy, A. N. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.113968 · Cited by 26

Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective

Alnefaie, A., & Albogami, S. M. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.024 · Cited by 25

COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection

Ghasemiyeh, P., & Mohammadi‐Samani, S. (2020) · Heart & Lung · doi:10.1016/j.hrtlng.2020.08.025 · Cited by 27

Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup

Berling, I., King, J. D., Shepherd, G., Hoffman, R. S., Alhatali, B., Lavergne, V., Roberts, D. M., Gosselin, S., Wilson, G., Nolin, T. D., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050564 · Cited by 26

Temperature-Based Topological Indices and QSPR Analysis of COVID-19 Drugs

Kansal, N., Garg, P., & Singh, O. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2086271 · Cited by 26

Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options

Singh, V., & Mishra, V. (2020) · Coronaviruses · doi:10.2174/2666796701999201005211854 · Cited by 26

COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels

Szendrey, M., Guo, J., Li, W., Yang, T., & Zhang, S. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000484 · Cited by 26

COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

Carpenter, A., Chambers, O. J., Harchi, A. E., Bond, R. C., Hanington, O., Harmer, S. C., Hancox, J. C., & James, A. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00085 · Cited by 26

A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs

Yu, W., Toh, H. S., Liao, C., & Chang, W. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07024-7 · Cited by 25

Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach

Achilonu, I., Iwuchukwu, E. A., Achilonu, O., Fernandes, M. A., & Sayed, Y. (2020) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2020.107730 · Cited by 25

Can we use hydroxychloroquine to treat COVID-19 now?

Chen, J., Liu, D., Yin, L., Zhang, L., & Lu, H. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106173 · Cited by 1

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Sahraei, Z., Shabani, M., Shokouhi, S., & Saffaei, A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105945 · Cited by 234

Chloroquine and hydroxychloroquine as potential therapies against COVID-19

Yewange, S., Deshpande, R. R., Waghmare, N., Vidyasagar, G., Bavage, S. B., & Bavage, N. B. (2020) · Cited by 1

Chloroquine as a prophylactic agent against COVID-19?

Gendrot, M., Javelle, É., Clerc, A., Savini, H., & Pradines, B. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105980 · Cited by 44

Chloroquine for the 2019 novel coronavirus SARS-CoV-2

Colson, P., Rolain, J., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 471